Inflammatory Bowel Disease (IBD) Therapeutics Market Size

Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis

The Inflammatory Bowel Disease Therapeutics Market size in terms of Equal-5.15 is expected to grow from USD 24.46 billion in 2024 to USD 31.43 billion by 2029, at a CAGR of 5.15% during the forecast period (2024-2029).

With the rise of COVID-19, there was a rise in other complications associated with IBD, such as Crohn’s disease (CD) and ulcerative colitis, that arise along with the infection. For instance, according to a report by the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus, upon entering the gastrointestinal tract, initiates activation of innate and adaptive immune responses. The onset of inflammatory reactions can supposedly induce intestinal damage in IBD patients. Thus, there was an increased demand for IBD therapeutics to manage further complications that could develop due to COVID-19. However, as the pandemic has subsided currently, the studied market is expected to have stable growth during the forecast period of the study.

The increasing occurrence of Crohn’s disease and ulcerative colitis is the major driver, which is predicted to boost the growth of the market. For instance, according to the data updated by Crohn’s & Colitis United Kingdom in 2022, it is estimated that 1 in every 123 people in the United Kingdom have either Crohn’s disease or ulcerative colitis, which amounts to a total of nearly half a million people in the United Kingdom living with IBD. The source also stated that research conducted in the United Kingdom also suggested that there is a significant chance of comorbidity between IBD and other inflammatory diseases, which means that people who have already received a diagnosis of IBD are more likely to be diagnosed with other inflammatory diseases in the future. Thus, the high burden of IBD is expected to boost the usage of its therapeutics during the forecast period.

An increase in the approval of biologics and the presence of robust pipeline products are expected to propel the growth of the market. For instance, according to an article published by the World Journal of Clinical Cases in April 2023, biologic agents have been widely used in the management of inflammatory bowel disease (IBD) for many years, and currently, there has been increasing interest and experience using dual biologic therapy (DBT) in IBD, primarily in difficult to treat and refractory cases with high disease burden. The increasing use of biologic therapies in IBD patients provides lucrative opportunities for market growth attributed to the vast costs of biologics.

However, a lack of awareness among people about IBD is expected to limit the growth of the market.